<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04816123</url>
  </required_header>
  <id_info>
    <org_study_id>2017-MB-DNFN-16</org_study_id>
    <nct_id>NCT04816123</nct_id>
  </id_info>
  <brief_title>The Mass Balance and Biotransformation of [14C]Donafenib in Healthy Adult Man</brief_title>
  <official_title>The Mass Balance and Biotransformation Study of [14C] Donafenib in Chinese Healthy Adult Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the mass balance and biotransformation after single-dose&#xD;
      of [14C]Donafenib orally in Chinese healthy adult male volunteers, revealing the overall&#xD;
      pharmacokinetic characteristics of Donafenib in humans, and providing a reference for the&#xD;
      rational administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2018</start_date>
  <completion_date type="Actual">December 18, 2018</completion_date>
  <primary_completion_date type="Actual">December 18, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>single arm with single dose of 300mg Donafenib, containing about 120μCi [14C]Donafenib</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Nonrandomized and open labeled study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitive analysis of whole radioactivity of excrement of orally administered [14]Donafenib in Chinese healthy adult male volunteers to obtain the mass balance data and the main excretion pathway in human body</measure>
    <time_frame>from 0 hour to 240 hours after administration</time_frame>
    <description>The percentage of radioactive dose of [14C] radiolabelled Donafenib recovered in urine, faeces and in total</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of the main metabolite and biotransformation pathway of Donafenib and investigation of metabolite in plasma by LC-RAM/HRMS</measure>
    <time_frame>from 0 hour to 240 hours after administration</time_frame>
    <description>Proportion of different metabolites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitive analysis of the concentrations of Donafenib in plasma using the validated LC-MS/MS to obtain pharmacokinetic data</measure>
    <time_frame>from 0 hour to 240 hours after administration</time_frame>
    <description>The concentrations of Donafenib in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 7 days (approx) from the start of administration</time_frame>
    <description>Review the relationship between investigational products and all the abnormal and clinically significant findings</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Male Adult</condition>
  <arm_group>
    <arm_group_label>[14C]Donafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]Donafenib</intervention_name>
    <description>Each volunteers received a single 300 mg dose of [14C]donafenib (toluene sulfonic acid) containing a radioactivity dose of 120 μCi as an oral suspension, in fasting within 5 minutes.</description>
    <arm_group_label>[14C]Donafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A healthy male adult.&#xD;
&#xD;
          -  Age is between 18 and 45, inclusive.&#xD;
&#xD;
          -  Body mass index is between 19 and 26, inclusive.&#xD;
&#xD;
          -  Voluntarily to provide informed consent form.&#xD;
&#xD;
          -  Willing and able to communicate with investigators and complete the trial according to&#xD;
             clinical trial protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any abnormal and clinical significant findings.&#xD;
&#xD;
          -  A positive examination result of HBsAg/HBeAg, HIV antibody and treponema pallidum&#xD;
             antibody.&#xD;
&#xD;
          -  Volunteers who had participated in a radiolabeled clinical study or were exposed to&#xD;
             significant levels of radiation for any reasons within the 12 months prior to the&#xD;
             study.&#xD;
&#xD;
          -  Volunteers who had used of prescription or herbal products that may affect the drug&#xD;
             metabolism within 30 days before the study.&#xD;
&#xD;
          -  Volunteers who had blood loss/donation up to 400 mL within 3 months before the&#xD;
             screening, or received blood transfusion within 1 month.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liyan Miao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Suzhou Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

